Q2/2009: Merck Revenues Remain Steady at ? 1.9 Billion

• Rebif sales up 21% to € 387 million; Erbitux sales rise 18% to € 171 million • Liquid Crystals improves, revenues at € 189 million, ROS at 27.4% • Operating result declines 42% to € 184 million • Merck remains on track to meet Group guidance for 2009

DARMSTADT, Germany, July 24, 2009 - Merck KGaA announced today that Group total revenues were steady in the second quarter and in the first half of 2009 at € 1,902 million and € 3,756 million, respectively. Royalty income was down 14% to € 75 million in the second quarter but up 7.0% to € 173 million in the first half. The gross margin declined by 2.1% to € 1,384 million in the second quarter and by 1.4% to € 2,781 million in the half year.

 

The complete results can be downloaded at the following link: http://news.merck.de/N/0/9C9A0904615A9F68C12575FC0045CFC3/$File/Q2-09-e.pdf

 

Contact Phyllis Carter +49 6151 72-7144

Posted: July 2009


View comments

Hide
(web3)